[go: up one dir, main page]

AR118278A2 - Compuestos derivados de piperazinil-alquil-4(3h)-quinazolinonas - Google Patents

Compuestos derivados de piperazinil-alquil-4(3h)-quinazolinonas

Info

Publication number
AR118278A2
AR118278A2 ARP200100632A ARP200100632A AR118278A2 AR 118278 A2 AR118278 A2 AR 118278A2 AR P200100632 A ARP200100632 A AR P200100632A AR P200100632 A ARP200100632 A AR P200100632A AR 118278 A2 AR118278 A2 AR 118278A2
Authority
AR
Argentina
Prior art keywords
quinazolinones
alkyl
ethyl
methoxyphenyl
piperazinil
Prior art date
Application number
ARP200100632A
Other languages
English (en)
Inventor
Torres Russo Valter Freire
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Ache Int Bvi Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa, Ache Int Bvi Ltd filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of AR118278A2 publication Critical patent/AR118278A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos derivados de piperazinil-alquil-4(3H)-quinazolinonas que poseen alta afinidad por los receptores 5-HT₁A y 5-HT₂A para el tratamiento de trastornos asociados. Reivindicación 1: Compuesto derivado de piperazinil-alquil-4(3H)-quinazolinonas caracterizado por presentar la fórmula general (1) donde, n = 2, R¹ es hidrógeno o etilo y R² está seleccionado del grupo que consiste de 3-trifluormetilfenil, 2-clorofenil, 2-metilfenil, 2,3-dimetilfenil, 2-cianofenil, y 2-metoxifenil, o una sal farmacéuticamente apropiada del mismo, seleccionado del grupo que consiste de: 3-(2-(4-(2-metoxifenil)piperazin-1-il)etil)quinazolin-4(3H)-ona; y 2-etil-3-(2-(4-(2-metoxifenil)piperazin-1-il)etil)quinazolin-4(3H)-ona.
ARP200100632A 2010-09-24 2020-03-06 Compuestos derivados de piperazinil-alquil-4(3h)-quinazolinonas AR118278A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI1003506-0 BRPI1003506B1 (pt) 2010-09-24 2010-09-24 composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Publications (1)

Publication Number Publication Date
AR118278A2 true AR118278A2 (es) 2021-09-22

Family

ID=44903021

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110103473A AR083166A1 (es) 2010-09-24 2011-09-22 Derivados de alquil-piperazin-fenil 4(3h)-quinazolinonas utiles para tratar depresion, ansiedad, disfunciones sexuales femeninas y otras patologias del sistema nervioso central, y composiciones farmaceuticas que los contienen
ARP200100632A AR118278A2 (es) 2010-09-24 2020-03-06 Compuestos derivados de piperazinil-alquil-4(3h)-quinazolinonas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110103473A AR083166A1 (es) 2010-09-24 2011-09-22 Derivados de alquil-piperazin-fenil 4(3h)-quinazolinonas utiles para tratar depresion, ansiedad, disfunciones sexuales femeninas y otras patologias del sistema nervioso central, y composiciones farmaceuticas que los contienen

Country Status (12)

Country Link
US (6) US8735578B2 (es)
EP (1) EP2619187B1 (es)
AR (2) AR083166A1 (es)
BR (1) BRPI1003506B1 (es)
CL (1) CL2012003539A1 (es)
CO (1) CO6650398A2 (es)
DK (1) DK2619187T3 (es)
ES (1) ES2538105T3 (es)
MX (1) MX2013002955A (es)
PE (1) PE20130512A1 (es)
PT (1) PT2619187E (es)
WO (1) WO2012037634A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016186909A1 (en) 2015-05-18 2016-11-24 Mayo Foundation For Medical Education And Research Percutaneously-deployable prosthetic tricuspid valve
EP3130339B1 (en) * 2015-08-14 2020-05-06 Aché Laboratórios Farmacêuticos S.A. A compound for use in the treatment of comorbid anxiety disorder and depression disorder
JP2021506796A (ja) * 2017-12-14 2021-02-22 アシェ・ラボラトリオス・ファルマセウティクス・エス・アー 外傷後症候群障害の治療
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
US20240207338A1 (en) * 2021-04-30 2024-06-27 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
IL319150A (en) 2022-08-26 2025-04-01 Suven Life Sciences Ltd Heteroaromatic compounds for the treatment of neurological disorders

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB420398A (en) 1933-08-28 1934-11-30 Stanley John Corbin Improvements in clips for making electrical connections
US3047462A (en) 1959-03-06 1962-07-31 Lab Jacques Logeais Soc D Expl Quinazolone anti-inflammatory composition
US3086910A (en) 1960-03-09 1963-04-23 Wallace & Tiernan Inc Central nervous system depressants 3-(2'-pyridyl)-4-quinazolones
US3073826A (en) 1960-10-20 1963-01-15 Mead Johnson & Co 3-pyrrolidylmethyl-4-quinazolones
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
US3231572A (en) 1963-08-05 1966-01-25 Miles Lab 3-substituted-4-quinazolones
US3448109A (en) 1966-08-01 1969-06-03 Boehringer Sohn Ingelheim Certain amino-substituted 2-methyl-3-phenyl-4(3h)-quinazolinones
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
US3726979A (en) 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
GB1466571A (en) 1973-10-23 1977-03-09 Roussel Lab Substituted quinazolone compounds and pharmaceutical uses thereof
GB1560271A (en) 1977-01-14 1980-02-06 Joullie International Sa Therapeutically useful m-trifluoromethylphenylpiperazine derivatives
FR2429212A1 (fr) 1978-06-20 1980-01-18 Synthelabo Derives de phenylpiperazine et leur application en therapeutique
FI791926A7 (fi) 1978-06-20 1979-12-21 Synthelabo Fenylpiperazinderivat
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
US4721787A (en) 1984-05-10 1988-01-26 Ciba-Geigy Corporation Process for the preparation of benzo-(pyrano and thiopyrano)-pyridines
ATE64735T1 (de) 1984-05-10 1991-07-15 Ciba Geigy Ag Benzo-(pyrano und thiopyrano)-pyridine.
JPS62135464A (ja) 1985-12-10 1987-06-18 Nippon Kayaku Co Ltd フエニルピペラジン誘導体
US4866230A (en) 1987-04-27 1989-09-12 Shin-Etu Handotai Company, Limited Method of and apparatus for controlling floating zone of semiconductor rod
US4797489A (en) 1987-12-02 1989-01-10 American Home Products Corp. Adamantyl- and fluorenyl-arylpiperazines and -arylpiperidines
US5166157A (en) 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
EP0436157B1 (en) 1990-01-02 1995-08-23 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives and their preparation
IT1251144B (it) 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
SE9201239D0 (sv) 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
IT1313625B1 (it) 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US6586435B2 (en) 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors

Also Published As

Publication number Publication date
US20130184286A1 (en) 2013-07-18
MX2013002955A (es) 2013-10-01
PT2619187E (pt) 2015-06-30
EP2619187A1 (en) 2013-07-31
US20160008360A1 (en) 2016-01-14
DK2619187T3 (en) 2015-06-01
US20150018365A1 (en) 2015-01-15
BRPI1003506A2 (pt) 2013-01-29
US20140303179A1 (en) 2014-10-09
US20210338674A1 (en) 2021-11-04
ES2538105T3 (es) 2015-06-17
EP2619187B1 (en) 2015-03-04
BRPI1003506B1 (pt) 2019-12-03
WO2012037634A1 (en) 2012-03-29
CO6650398A2 (es) 2013-04-15
CL2012003539A1 (es) 2013-07-26
PE20130512A1 (es) 2013-04-27
US9169218B2 (en) 2015-10-27
US8735578B2 (en) 2014-05-27
US9326984B2 (en) 2016-05-03
US9181201B2 (en) 2015-11-10
US20140336199A1 (en) 2014-11-13
AR083166A1 (es) 2013-02-06

Similar Documents

Publication Publication Date Title
AR118278A2 (es) Compuestos derivados de piperazinil-alquil-4(3h)-quinazolinonas
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
AR078045A1 (es) Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer
PE20090770A1 (es) Derivados de benzoxazolona
BRPI0507574A (pt) piridazinonas como antagonistas de alfa 4 integrinas
CY1118016T1 (el) ΑΝΑΣΤΟΛΕΙΣ Ν1-ΠΥΡΑΖΟΛΟΣΠΕΙΡΟΚΕΤΟΝΗΣ ΑΚΕΤΥΛ-CoA ΚΑΡΒΟΞΥΛΑΣΗΣ
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
ES2570756T3 (es) Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
UY31083A1 (es) Derivados de sulfoximinas para la inhibicion de b-secretasa
AU2008245082A8 (en) Aminodihydrothiazine derivatives substituted with a cyclic group
UY31126A1 (es) Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
GEP20135730B (en) Trans-4-{2-[4-(2,3-dichlorophe-nyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treatment of schizophrenia
AR066421A1 (es) Compuestos derivados de piridona
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
AR077367A1 (es) 2- carboxamida -cicloamino-ureas sustituidas
AR073769A1 (es) Inhibidores de la integrasa del vih derivados de azepina y oxazepinas condensadas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por vih.